Literature DB >> 26916441

Assessment of the antidiarrhoeal properties of the aqueous extract and its soluble fractions of Chebulae Fructus (Terminalia chebula fruits).

Zunlai Sheng1, Xin Yan1, Ruili Zhang1, Huilin Ni1, Yuanxu Cui1, Junwei Ge1, Anshan Shan2.   

Abstract

Context Chebulae Fructus is used as an herbal remedy for diarrhoea in traditional Chinese medicine. However, there is no scientific evidence to support its antidiarrhoeal activity. Objective This study evaluates the antidiarrhoeal properties of Chebulae Fructus aqueous extract (CFAE) and determines the active fraction. Materials and methods The antidiarrhoeal effect of CFAE (200-800 mg/kg) was investigated by determining the wet dropping, intestinal transit in BALB/c mice and enteropooling in Wister rats. The protective effects of the CFAE on the intestinal and liver were tested by histopathological analyses. The antidiarrhoeal fraction was determined by castor oil-induced diarrhoea and its main constituents were identified by HPLC-ESI-MS. Results The extract at doses of 200, 400 and 800 mg/kg reduced the diarrhoea by 9.1, 40.0 and 58.2% and inhibited intestinal transit by 18.3, 24.1 and 35.7%, respectively. Additionally, the CFAE (200, 400 and 800 mg/kg) decreased the volume of enteropooling by 47.1, 58.8 and 64.7%, respectively. Mice treated with castor oil presented morphological alterations in the small intestine and the liver. However, the lesions of mice treated with CFAE were alleviated. Moreover, the ethyl acetate fraction was the active fraction of CFAE, the fraction (41.7, 83.4 and 166.8 mg/kg) reduced the diarrhoea by 9.1, 38.2 and 54.5%, respectively. The major components of the ethyl acetate fraction were tannins, including gallic acid, 3, 4, 6-tri-O-galloyl-β-d-Glc, corilagin and ellagic acid according to the HPLC-ESI-MS analysis. Conclusion The CFAE possessed antidiarrhoeal property and the ethyl acetate fraction was its main active fraction.

Entities:  

Keywords:  Antidiarrhoeal fraction; HPLC-ESI-MS; histopathological analyses

Mesh:

Substances:

Year:  2016        PMID: 26916441     DOI: 10.3109/13880209.2015.1131993

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  7 in total

Review 1.  The Modern Use of an Ancient Plant: Exploring the Antioxidant and Nutraceutical Potential of the Maltese Mushroom (Cynomorium Coccineum L.).

Authors:  Paolo Zucca; Sidonie Bellot; Antonio Rescigno
Journal:  Antioxidants (Basel)       Date:  2019-08-07

Review 2.  Gallic Acid and Diabetes Mellitus: Its Association with Oxidative Stress.

Authors:  Yu Xu; Guoyi Tang; Cheng Zhang; Ning Wang; Yibin Feng
Journal:  Molecules       Date:  2021-11-24       Impact factor: 4.411

3.  Elucidating the material basis and potential mechanisms of Ershiwuwei Lvxue Pill acting on rheumatoid arthritis by UPLC-Q-TOF/MS and network pharmacology.

Authors:  Chuan Liu; Fangfang Fan; Lu Zhong; Jinsong Su; Yi Zhang; Ya Tu
Journal:  PLoS One       Date:  2022-02-07       Impact factor: 3.240

Review 4.  Phytotherapeutic Approaches to the Prevention of Age-Related Changes and the Extension of Active Longevity.

Authors:  Olga Babich; Viktoria Larina; Svetlana Ivanova; Andrei Tarasov; Maria Povydysh; Anastasiya Orlova; Jovana Strugar; Stanislav Sukhikh
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411

Review 5.  A comprehensive review on the diverse pharmacological perspectives of Terminalia chebula Retz.

Authors:  Md Rakibul Hassan Bulbul; Mohammad Nizam Uddin Chowdhury; Taslima Anjum Naima; Saad Ahmed Sami; Md Shakil Imtiaj; Nazmul Huda; Md Giash Uddin
Journal:  Heliyon       Date:  2022-08-14

Review 6.  Mongolian medicine: History, development and existing problems.

Authors:  Songbo Qu; Jinshan Bao; Wuliji Ao; Laxinamujila Bai; Almaz Borjigidai
Journal:  Chin Herb Med       Date:  2022-07-20

Review 7.  A Comprehensive Review of the Structure Elucidation of Tannins from Terminalia Linn.

Authors:  Zihao Chang; Qiunan Zhang; Wenyi Liang; Kun Zhou; Ping Jian; Gaimei She; Lanzhen Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-15       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.